The cortical AChE-activity used to quantify the ‘cholinergic deficit’ here has previously been linked to the response to a single dose of the cholinomimetic rivastigmine under controlled conditions.5 However, the findings from that study cannot be translated directly to the current observations, as that study only included AD biomarker positive patients at the stage of MCI, while current sample also included patients with mild dementia and unknown CSF status, i.e., a much more diverse sample. The gene discussed is ACHE; the disease is dementia.